PD-1 immune checkpoint blockade can synergize with PSGL-1 inhibition to reinvigorate exhausted T cells
نویسندگان
چکیده
Abstract P-selectin glycoprotein ligand-1 (PSGL-1) is an immune checkpoint regulator that highly expressed on T cells. PSGL-1- deficient mice infected with chronic lymphocytic choriomeningitis virus (LCMV) were shown to control viral infection due increased effector function by anti-viral However, the cell-intrinsic role of PSGL-1 expression CD4 +and CD8 +T cell exhaustion not fully known. Using adoptive transfers WT or PSGL-1-deficient TCR transgenic cells in LCMV, we characterized differentiation and response. We found expansion early during infection, however, at later stages functionally exhausted. exhausted +PSGL-1-deficient reinvigorated more effectively than after PD-L1 blockade their proliferation, cytokine production, accumulation. also observed responses melanoma tumors. Our findings showed was required for maintenance both +exhausted deletion synergized PD-1 reinvigorate these These highlight important reinvigoration T32 AI 141346 R01 AI13723
منابع مشابه
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
The programmed death (PD)-1-PD-1 ligand (PD-L) pathway, which is part of the B7-CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, and recent work has shown that PD-1 is highly expressed on exhausted T cells during chronic lymphocytic choriomeningitis virus (LCMV) infection in mice. Blockade of this pathwa...
متن کاملHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors. Here, we investigated whether programmed death-1-mediated (PD-1-mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and ex...
متن کاملImmune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunotherapy has evolved as a new pillar of cancer treatment during the last decade. The main breakthrough was the development of immune checkpoint blocking (ICB) antibodies, which antagonize inhibitory receptors on T cells and their ligands and thus unleash the cellular immune system against the tumor. ICB showed tremendous effects in several types of cancer. However, only a proportion of the...
متن کاملPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade...
متن کاملPD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy. However, current immune checkpoint-based therapies are successful only in a subset of patients and acquired resistances pose additional challenges. Finding new targets and combining checkpoint inhibitors might help to overcome...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Immunology
سال: 2023
ISSN: ['1550-6606', '0022-1767']
DOI: https://doi.org/10.4049/jimmunol.210.supp.59.23